Jianhua Gu

Dr. Jianhua Gu

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JGJianhua Gu
Jianhua Gu
CLCui-Cui Liu
Cui-Cui Liu
JXJin-Lan Xie
Jin-Lan Xie
BMBin Ma
Bin Ma
SCShao-Min Cui
Shao-Min Cui
SHShun-Cheng He
Shun-Cheng He
Non-small cell lung cancer (NSCLC) is a prevalent malignancy with high mortality and poor prognosis. Bupivacaine serves as a widely used local anesthetic and presents potential anti-tumor activity. Nevertheless, the function of bupivacaine in the NSCLC development remains elusive. Here, we tried to investigate the impact of bupivacaine on the NSCLC progression. Significantly, we revealed that bupivacaine was able to reduce the proliferation and induce the apoptosis of NSCLC cells. Bupivacaine could attenuate the invasion and migration in the cells. Mechanically, the treatment of bupivacaine increased the expression ratio of light chain 3B-II (LC3B-II)/LC3B-I and the expression of Beclin-1 in the NSCLC cells. Meanwhile, the expression of the autophagic adaptor protein p62 was decreased by bupivacaine treatment in the cells. The treatment of bupivacaine attenuated the phosphorylation of AKT and mTOR in the NSCLC cells. The AKT activator SC79 and autophagy inhibitor 3-methyladenine (3-MA) reversed the bupivacaine-inhibited phosphorylation of AKT and mTOR and bupivacaine-induced autophagy, as well as the bupivacaine-attenuated NSCLC progression in the cells. Bupivacaine could inhibit the tumor growth in vivo. In conclusion, we discovered that the local anesthetic bupivacaine inhibited the progression of NSCLC by inducing autophagy through Akt/mTOR signaling. Our finding provides new insights into the mechanism by which bupivacaine attenuates the development of NSCLC. Bupivacaine may serve as a potential anti-tumor candidate for the therapeutic strategy of NSCLC.

20 June 2025 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
JGJianhua Gu
Jianhua Gu
ZZZhaolei Zheng
Zhaolei Zheng
JLJiqing Li
Jiqing Li
SWShuo Wu
Shuo Wu
HSHeming Sun
Heming Sun
YCYuguo Chen
Yuguo Chen
Aims: Heart failure (HF) is a major global public health concern, particularly in older adults (aged ≥65 years). Despite its growing prevalence, comprehensive analyses of HF burden in this population, including trends, causes, and socioeconomic disparities, remain limited. Methods and results: Using data from the Global Burden of Disease (GBD) Study 2021, we analysed the burden of HF among older adults from 1990 to 2021, including prevalence, years lived with disability (YLDs), and underlying causes. We conducted a decomposition analysis to quantify the contributions of population growth, ageing, and epidemiological changes and projected future trends to 2035 using Bayesian Age-Period-Cohort modelling. From 1990 to 2021, global HF cases among older adults increased from 14.1 million to 36.2 million, whereas YLDs rose from 1.34 million to 3.45 million. Population growth accounted for 89.0% of the increase in both prevalence and YLDs, while the ageing effect varied by Sociodemographic Index (SDI) quintiles, showing negative contributions (−39.4%) in high-SDI regions and positive contributions (+28.7%) in middle-SDI regions. Globally, ischaemic heart disease was the leading cause of death (37.6%) across all SDI quintiles, followed by hypertensive heart disease (24.1%). The low-to-middle SDI regions experienced the fastest growth in HF burden (EAPC = 0.22), with socioeconomic inequality widening over time. Projections suggest that age-standardized prevalence and YLDs will rise to 4935 cases and 473 years lived with disability per 100 000 population, respectively, by 2035. Conclusion: Global heart failure burden in older adults is escalating fastest in low-middle SDI regions due to population growth and healthcare inequities. Mitigating this crisis requires prioritizing equitable access to evidence-based therapies and addressing socioeconomic disparities in ageing populations.

29 March 2022 in Cancer Medicine
Verified
Journal Article
Open access
ZFZhiyuan Fan
Zhiyuan Fan
YQYu Qin
Yu Qin
JZJing Zhou
Jing Zhou
RCRu Chen
Ru Chen
JGJianhua Gu
Jianhua Gu
WWWen-Qiang Wei
Wen-Qiang Wei
Background: Early diagnosis and treatment of esophageal squamous cell dysplasia (ESCdys) and esophageal squamous cell carcinoma (ESCC) could significantly reduce the incidence and mortality of ESCC. This pilot study aimed to investigate whether P16/CDKN2A methylation could serve as a cytologic biomarker for early detection of ESCdys and ESCC.Methods: Paired esophageal biopsy and cytology specimens (exfoliated cells) were obtained from subjects at different stages of ESCC development. The methylation status of P16 gene in these two specimen types was determined using a 115‐bp MethyLight assay. Categorical data were compared by the Chi‐square test. Logistic regression was performed to assess adjusted odds ratios of P16 methylation associated with ESCC and ESCdys. Prediction models for identifying individuals at risk of ESCC and high‐grade ESCdys (high‐grade intraepithelial neoplasia, HGIN) were developed by multivariable logistic regression. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. Internal validation of the prediction models was performed using the 1000‐bootstrap resample.Results: A total of 105 subjects with diagnoses ranging from normal mucosa through ESCC were included in this study. An increase in P16 methylation frequency was observed with increasing severity of esophageal lesions (p for trend <0.001). In the adjusted logistic regression models, P16 methylation in cytology specimens was positively associated with ESCC and ESCdys risk, whereas P16 methylation in biopsy specimens was only associated with a higher risk of developing ESCC. The predictive capacity of base model I (AUC, 0.816) for ESCC and HGIN was significantly increased by adding P16 methylation in cytology specimens (model III; AUC, 0.882; p = 0.043), but not P16 methylation in biopsy specimens (model II; AUC, 0.850; p = 0.225). Bootstrap validation showed optimism‐corrected AUC of 0.789 for model I, 0.822 for model II, and 0.854 for model III.Conclusion: P16 methylation as a cytologic marker was associated with the ESCC development and has the potential for application in minimally invasive ESCC screening.

25 October 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JLJiqing Li
Jiqing Li
WZWei Zhao
Wei Zhao
JYJia Yang
Jia Yang
PLPeipei Lu
Peipei Lu
HSHeming Sun
Heming Sun
JGJianhua Gu
Jianhua Gu
Cardia gastric cancer (CGC) is prevalent in East Asia, and noninvasive, cost-effective screening methods are needed. This study investigated the diagnostic value of serum pepsinogen (PG), gastrin-17 (G-17), Helicobacter pylori (H. pylori) antibodies, and proteomic profiling for CGC and precancerous lesions. We conducted a case-control study involving biopsy-confirmed patients with CGC (n = 60), low-grade intraepithelial neoplasia (CLGD, n = 60), high-grade intraepithelial neoplasia (CHGD, n = 64), and healthy controls (n = 120) matched for age and sex from high-incidence areas in China. Serological markers including PGI, PGII, G-17, and H. pylori were measured using ELISA and Western blot, while plasma protein markers were assessed using Olink® technology. The VSOLassoBag algorithm and nine machine learning (ML) algorithms were employed to identify crucial features and construct predictive models. Various evaluation metrics, including the area under the receiver-operating-characteristic curve (AUC), were utilized to compare predictive performance. Elevated PGII levels, decreased PGR, and H. pylori infection were significantly associated with an increased risk of CGC and precancerous lesions (P for trend < 0.05). The eXtreme Gradient Boosting (XGBoost) model performed best in discriminative ability among the 9 ML models. Following feature reduction based on predictive performance, a final explainable XGBoost model was developed, incorporating five protein biomarkers (CDHR2, ICAM4, PTPRM, CDC27, and FLT1). This model exhibited excellent performance in distinguishing individuals with CGC and precancerous lesions from healthy controls (AUC = 0.931 for CGC, 0.867 for CHGD, and 0.763 for CLGD), surpassing the traditional serological marker-based model. This study underscores the diagnostic potential of serological markers and proteomic profiling in the detection of CGC. Further validation and exploration of combined biomarker approaches are warranted to enhance early diagnosis and improve outcomes in high-risk populations.

14 January 2026 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
GCGuanmin Cui
Guanmin Cui
KJKai Jing
Kai Jing
YLYunxia Li
Yunxia Li
JGJianhua Gu
Jianhua Gu
FLFang Li
Fang Li
Background: The global incidence of early-onset colorectal cancer (EOCRC) is rising. We compared trends in dietary fiber intake, a key modifiable risk factor, and its attributable EOCRC burden among young adults in China versus globally from 1990 to 2021. Methods: Using data from the GDD and GBD 2021 for adults aged 25–49, we analyzed age-standardized mean fiber intake, summary exposure value (SEV) for low intake, and attributable EOCRC mortality and disability-adjusted life years (DALYs). Trends were quantified using the estimated annual percentage change (EAPC). Results: Between 1990 and 2018, China’s mean dietary fiber intake increased dramatically from 5.0 to 23.3 g/day (EAPC 5.73%), substantially outpacing the global increase (EAPC 1.41%). This led to a profound reversal in risk exposure; China’s SEV for low fiber declined at nearly twice the global rate (EAPC −2.14% vs −1.15%), falling below the global benchmark after 2005. Consequently, the attributable age-standardized mortality rate in China dropped from 0.15 per 100,000 to converge with the global level of 0.05 by 2021 (EAPC −3.81% vs −2.17% globally). Similar rapid declines occurred for DALYs and were more pronounced in women. Favorable epidemiological changes were the primary driver of this reduction. Conclusion: China’s success in reducing its EOCRC burden from low dietary fiber highlights nutritional improvement as a potent primary prevention strategy, reinforcing the urgent need to promote fiber-rich diets globally.

5 May 2025 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
PWPeizhu Wang
Peizhu Wang
ZZZhaolei Zheng
Zhaolei Zheng
KWKui Wang
Kui Wang
JGJianhua Gu
Jianhua Gu
YLYanqing Li
Yanqing Li
Background Colorectal cancer (CRC) incidence and mortality are rising in China, with high body mass index (BMI) established as a significant risk factor. However, comprehensive evidence regarding the BMI-attributable CRC burden in the Chinese population remains limited. Objective This study aims to analyze the trend of CRC burden attributable to high BMI (BMI ≥ 25 kg/m2) in China from 1990 to 2021 and to predict its development from 2022 to 2035, in order to provide a scientific foundation for the formulation of public health policies. Methods We analyzed data from the Global Burden of Disease Study 2021 (GBD 2021) to assess the BMI-attributable CRC burden in China from 1990 to 2021. Temporal trends were analyzed using Joinpoint regression models. Future projections through 2035 were generated using Bayesian age-period-cohort (BAPC) modeling. The Das Gupta method was used to explore the contribution of population growth, aging, and epidemiologic factors to these burden changes. Results From 1990 to 2021, China’s BMI-attributable CRC burden increased substantially, with ASMR and ASDR rising at annual rates of 2.393% (95% CI 2.306–2.481) and 2.305% (95% CI 2.188–2.422), respectively. The mortality and disability-adjusted life years (DALYs) rate both increased with age. Males showed higher burden rates in most age groups. Projections indicate continued increases in ASMR (2.43% annually) and ASDR (2.44% annually) through 2035. Epidemiological factors were the primary drivers, contributing 99.73% to mortality changes and 44.81% to DALYs changes. Conclusions The BMI-attributable CRC burden in China shows a concerning upward trajectory that is predicted to continue, with epidemiologic factors playing a major role. Urgent public health interventions targeting obesity prevention, lifestyle modification, and expanded CRC screening are needed to mitigate this growing burden.